| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 80 | 50 | 80 | 60 | 60 |
| Sales Growth | +60.00% | -37.50% | +33.33% | unch | +20.00% |
| Net Income | -7,230 | -6,990 | -4,910 | -7,610 | -4,950 |
| Net Income Growth | -3.43% | -42.36% | +35.48% | -53.74% | -6.68% |
Aclarion Inc (ACON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Aclarion Inc. is a healthcare technology company which leverages Magnetic Resonance Spectroscopy and a proprietary biomarker to optimize clinical treatments. The Company is also researching the application of AI and machine learning platforms to analyze both the raw spectroscopy data and the post-processed signal to evaluate whether AI platforms. Aclarion Inc. is based in SAN MATEO, CA.
Fiscal Year End Date: 12/31